SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3152And there was good rationale to go after malignant brain tumor (probably not witMiljenko Zuanic-1/4/2018
3151With related note, PFE/Roche are out: pubs.acs.org So, what is wrong with 1000mMiljenko Zuanic-1/4/2018
3150IDO/PD1 . . . Here's is INCY's presentation, which dose give demotuck-9/9/2017
3149IDO/PD1 combo battle part 2: Here is the data for Epacadostat/Keytruda in melantuck-9/9/2017
3148Regards the INCY (and many others bio-comp) PGS knows much more than I do. BestMiljenko Zuanic-9/8/2017
3147Certainly is. Landscape changing fast. Which is a good thing, unless you'rscaram(o)uche-9/8/2017
3146It is also big push for GLPG/GILD! JAK1-3 and STAT are downstream of the IL4/13Miljenko Zuanic-9/7/2017
3145Wow. prnewswire.com <i>NORTH CHICAGO, Ill., Sept. 7, 2017 /PRNewswire/ -scaram(o)uche-9/7/2017
3144Yup, results look comparable to IO/IO (20% CR) with +12m PFS. If results hold iMiljenko Zuanic-9/7/2017
3143Took awhile for that trade to pay, hope you didn't sell for that dinner monescaram(o)uche-9/7/2017
3142Updated Indoximod/Keytruda data: Updated Data for Indoximod Plus KEYTRUDA®tuck-9/7/2017
3141Epacadostat + Pembrolizumab at ESMO, drilling into the melanoma cohort now: >tuck-8/31/2017
3140<So, I get what MZ and AF are saying. Indoximod seems to work by by targetingMiljenko Zuanic-6/8/2017
3139Navoximod, OTOH, appears to be a direct inhibitor of IDO. Here's the underltuck-6/8/2017
3138The compounds certainly have different structures. The article you mention appetuck-6/8/2017
3137Feuerstein is referring to a manuscript, maybe published ~ 3 years ago?? Said iscaram(o)uche-6/8/2017
3136I need a list of combo's that have failed. And I hate having to google a trscaram(o)uche-6/8/2017
3135Indox mode of action and target is completely different than Ecap, so any similaMiljenko Zuanic-6/8/2017
3134Maybe I'm forgetting something. Indoximod/PD-1 combo looked nearly the sametuck-6/8/2017
3133<If we assume indoximod is roughly equivalent to epacadostat...> It is noMiljenko Zuanic-6/8/2017
3132Probably need luck. Bought a second and last slug at $7.10 (so cost =$7.25), antuck-6/8/2017
3131Wouldn't be my choice for a trade, but wishing you luck.scaram(o)uche-6/8/2017
3130All the IDO inhibitors showed stable disease as the best response in P1. I'tuck-6/8/2017
3129Roche says bye-bye to their number one IDO squeeze.... investors.linkp.com Howscaram(o)uche-6/8/2017
3128link from @bradloncar pbs.twimg.comscaram(o)uche-6/5/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News